Arylpiperazines 2–11 were synthesized, and their biological profiles at α1-adrenergic receptors (α1-ARs) assessed by binding assays in CHO cells expressing human cloned subtypes and by functional experiments in isolated rat vas deferens (α1A), spleen (α1B), and aorta (α1D). Modifications at the 1,3-benzodioxole and phenyl phamacophoric units resulted in the identification of a number of potent compounds (moderately selective with respect to the α1b-AR), in binding experiments. Notably, compound 7 (LDT451) showed a subnanomolar pKi of 9.41 towards α1a-AR. An encouragingly lower α1B-potency was a general trend for all the series of compounds, which showed α1A/D over α1B selectivity in functional assays. If adequately optimized, such peculiar selectivity could have relevance for a potential LUTS/BPH therapeutic application.
Synthesis and structure–activity relationships of novel arylpiperazines as potent antagonists of α1-adrenoceptor / Silva, Renata Oliveira; de Oliveira, Andressa Souza; Nunes Lemes, Laís Flávia; de Camargo Nascente, Luciana; Coelho do Nascimento Nogueira, Patrícia; Silveira, Edilberto R.; Brand, Guilherme D.; Vistoli, Giulio; Cilia, Antonio; Poggesi, Elena; Buccioni, Michela; Marucci, Gabriella; Bolognesi, Maria Laura; Romeiro, Luiz Antonio Soares. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - STAMPA. - 122:(2016), pp. 601-610. [10.1016/j.ejmech.2016.06.052]
Synthesis and structure–activity relationships of novel arylpiperazines as potent antagonists of α1-adrenoceptor
BOLOGNESI, MARIA LAURA;
2016
Abstract
Arylpiperazines 2–11 were synthesized, and their biological profiles at α1-adrenergic receptors (α1-ARs) assessed by binding assays in CHO cells expressing human cloned subtypes and by functional experiments in isolated rat vas deferens (α1A), spleen (α1B), and aorta (α1D). Modifications at the 1,3-benzodioxole and phenyl phamacophoric units resulted in the identification of a number of potent compounds (moderately selective with respect to the α1b-AR), in binding experiments. Notably, compound 7 (LDT451) showed a subnanomolar pKi of 9.41 towards α1a-AR. An encouragingly lower α1B-potency was a general trend for all the series of compounds, which showed α1A/D over α1B selectivity in functional assays. If adequately optimized, such peculiar selectivity could have relevance for a potential LUTS/BPH therapeutic application.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
